MACK Merrimack Pharmaceuticals, Inc.

-0.06  -1.83%
Previous Close 3.27
Open 3.29
Price To book 0.00
Market Cap 416.06M
Shares 129,615,000
Volume 4,001,047
Short Ratio 17.94
Av. Daily Volume 3,230,110

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22 2015
Cancer - second line pancreatic
Phase 2 data due 1H 2018.
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
Cancer - HER2-positive locally advanced or metastatic breast cancer
Phase 2 initiated mid Feb 2015. Data due by end of 2018.
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
Cancer - front line pancreatic

Latest News

  1. Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments
  2. Macy’s, Teva Join Wednesday’s 52-Week Low Club
  3. Is the Options Market Predicting a Spike in Merrimack (MACK) Stock?
  4. DryShips, Merrimack Pharma Stuck in Tuesday’s 52-Week Low Club
  5. Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen
  6. Company News for January 10, 2017
  7. Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016
  8. Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
  9. So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction
  10. Merrimack Pharma to Sell Cancer Drugs for $1B
  11. Why Merrimack Pharmaceuticals Stock Is Roaring Higher Today
  12. Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion
  13. Biotech Stocks Surge Monday Amid Flurry of Deal Activity
  14. Monday’s 4 Biggest Biopharma Movers
  15. Merrimack Pharmaceuticals' stock soars on heavy volume after drug sale deal
  16. Stock Futures Mostly Lower as Crude Oil Slides Below $53
  17. MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with E
  18. France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal
  19. France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal
  20. France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal

SEC Filings

  1. DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material 17518619
  2. 8-K - Current report 17515803
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17515801
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161985204
  5. 8-K - Current report 161984273
  6. 8-K - Current report 161937351
  7. 8-K - Current report 161914469
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161808357
  9. 8-K - Current report 161807461
  10. 8-K - Current report 161718077